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Background: The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) and the Medical Outcomes
Study Short Form 36 (SF-36) are widely used to assess patient-reported outcome in individuals with pulmonary
hypertension (PH). The aim of the study was to compare the psychometric properties of the two measures.
Methods: Participants were recruited from specialist PH centres in Australia and New Zealand. Participants
completed the CAMPHOR and SF-36 at two time points two weeks apart. The SF-36 is a generic health status
questionnaire consisting of 36 items split into 8 sections. The CAMPHOR is a PH-specific measure consisting of 3
scales; symptoms, activity limitations and needs-based QoL. The questionnaires were assessed for distributional
properties (floor and ceiling effects), internal consistency (Cronbach's alpha), test-retest reliability and construct
validity (scores by World Health Organisation functional classification).
Results: The sample comprised 65 participants (mean (SD) age = 57.2 (14.5) years; n(%) male = 14 (21.5%)). Most of
the patients were in WHO class 2 (27.7%) and 3 (61.5%). High ceiling effects were observed for the SF-36 bodily
pain, social functioning and role emotional domains. Test-retest reliability was poor for six of the eight SF-36
domains, indicating high levels of random measurement error. Three of the SF-36 domains did not distinguish
between WHO classes. In contrast, all CAMPHOR scales exhibited good distributional properties, test retest reliability
and distinguished between WHO functional classes.
Conclusions: The CAMPHOR exhibited superior psychometric properties, compared with the SF-36, in the
assessment of PH patient-reported outcome.Background
Pulmonary hypertension (PH) is associated with progressive
elevation of pulmonary artery pressure (PAP) and pulmon-
ary vascular resistance (PVR), leading to right ventricular
failure and premature death [1]. Pulmonary arterial hyper-
tension is a rare condition with an estimated incidence of
2-7 per million per year [2,3]. However, incidence rates are
considerably higher when other subtypes of PH are consid-
ered [4]. Previous research has indicated a higher preva-
lence in females of around 1.5 to 3 times that of men [3].
PH presents with nonspecific symptoms, including dyspnea
on exertion, fatigue and syncope. These symptoms are often
difficult to separate from those caused by other disorders,
leading to late diagnosis [5]. Patients can experience
severe limitations in physical activity requiring lifestyle* Correspondence: jtwiss@galen-research.com
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reproduction in any medium, provided the ormodifications [6] and the inability to maintain employment
[7]. The psychological impact of PH can result in social iso-
lation, depression [8-10] and diminished quality of life [11].
Several types of outcome measure are available for
determining the impact of PH. Haemodynamic variables,
such as PVR, are often used as primary endpoints in
clinical trials. However, evidence shows that these do not
correlate well with the impact of the illness from the
patients’ perspective [12]. Measures of physical function,
such as the 6-minute walk distance (6MWD), are also fre-
quently used. Although these measures provide objective
data they do not capture the impact of the disease on
patients. Researchers often use patient-reported outcome
measures (PROMs) to determine the wider impact of PH
from the patient’s perspective.
There are two main types of PROMs; generic and
disease-specific. Generic outcome measures are used with
a wide range of illnesses. These measures are popular astd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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measure for each disease studied. One limitation of
generic measures is that they may not assess concerns
that are unique to each illness and important to patients.
Disease-specific measures are developed to assess the
specific concerns of the patient group [13].
The two most widely used PROMs with PH patients are
the Medical Outcomes Study Short-Form 36 general
health survey (SF-36) [14] and the Cambridge Pulmonary
Hypertension Outcome Review (CAMPHOR) [15]. The
SF-36 is a generic health-related quality of life (HRQL)
measure that has been used in several clinical trials for
PH. Despite this, limited information is available regarding
the psychometric properties of the SF-36 in a PH popula-
tion. Previous research has shown that the SF-36 corre-
lates with functional measures such as the 6MWD and
New York Heart Association assessment of functional
class [12]. In addition, there is some evidence that
the SF-36 is responsive in the PH population [16].
However, findings have been inconsistent and only
some of the SF-36 domains appear to be responsive
[17-19]. In addition, the investigation of scores representing
the minimal important difference (MID) of the SF-36 in
this patient group has shown that some of the domains of
the SF-36 have large MID values [20]. This implies
that large changes in scores are required to indicate a
real change in health status.
The CAMPHOR is a PH-specific measure and comprises
three scales assessing impairments (symptoms), activity
limitations (functioning) and quality of life (QoL). A further
development of the measure led to a utility scale for use in
economic evaluations [21]. The content for the measure
was derived directly from patient interviews and embodies
issues important to patients with PH. The CAMPHOR has
been shown to have good construct validity and reproduci-
bility [15]. All three scales have been shown to fit the Rasch
model providing evidence of unidimensionality. In
addition, there is evidence that the scales are responsive to
change [22]. Although the psychometric properties of the
CAMPHOR are promising, direct comparisons with other
measures are lacking.
The aim of this study was to conduct a direct
comparison of the psychometric properties of the
CAMPHOR and the SF-36 in a single population of
PH patients in order to determine the suitability of each
as an outcome measure.
Methods
Participants
The study utilizes data collected in Australia and New
Zealand [23]. Participants were men and women over
the age of 18 years, who met World Health Organisation
(WHO) [24] criteria for the diagnosis of PH. Participants
were required to be native English speaking and wereexcluded if they were unable to complete the question-
naires due to cognitive impairment. Ethics committees at
Royal Perth Hospital and Curtin University in Australia




The CAMPHOR was developed in the United Kingdom
(UK) [15] and subsequently adapted for use in Australia
and New Zealand [23]. It consists of three scales; the
Symptom Scale and QoL Scale both consist of 25 items
with a dichotomous response format (Yes/No). Scores can
range from 0-25 with a low score indicating minimal
symptoms or better QoL. The Activity Scale consists of 15
items with a 3 point rating system (Able to do on own
without difficulty/Able to do on own with difficulty/Unable
to do on own). Scores range from 0-30 with a low score
indicating minimal activity limitation.
SF-36; version 2
The SF-36 [14] is a generic health status questionnaire
consisting of eight domains; physical functioning (10 items),
social functioning (2 items), role limitations due to physical
problems (4 items), role limitations due to emotional
problems (3 items), mental health (5 items), energy/vitality
(4 items), pain (2 items), general health perception
(5 items) and a single health transition item. Raw
domain scores are transformed to a scale of 0-100 with
high scores indicating better health status.
Procedure
Details of the methodology are reported in full elsewhere
[23]. In brief, the study was conducted via postal survey.
Participants completed the SF-36 and CAMPHOR at
two time-points, two weeks apart. They also provided
demographic and disease information (age, gender, WHO
class and PH type). Participants completed the SF-36
immediately followed by the CAMPHOR at each time
point (Time 1 [T1] and Time 2 [T2]).
Statistical analyses
Data were analysed using SPSS Version 16.0. Data are
provided for T1 and T2 assessment points throughout
the results section.
Distributional properties
The distributional properties of the CAMPHOR and
SF-36 were examined using descriptive statistics including
mean, standard deviation, median, inter-quartile range
and range. The proportion of participants scoring the
minimum and maximum possible scores on the question-
naires was also assessed. This provides an indication of
the targeting of the questionnaire to the patient group. A
Table 1 Demographics of the study subjects (n=65)
Gender
Male (%) 14 (21.5)
Female (%) 51 (78.5)
Age
Mean (SD) 57.2 (14.5)
Median (IQR) 57.8 (47.5-67.8)
Range 20.1-87.5
WHO Classification
I (%) 3 (4.6)
II (%) 18 (27.7)
III (%) 40 (61.5)
IV (%) 4 (6.2)
PH Type
Idiopathic PAH (%) 37 (56.9)
Familial PAH (%) 1 (1.5)
Associated PAH (%) 23 (35.4)
Chronic thromboembolic PH (%) 2 (3.1)
PH associated with lung diseases (%) 2 (3.1)
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can indicate lack of sensitivity and/or relevance.
Internal consistency
Internal consistency was assessed using Cronbach’s alpha
coefficients for CAMPHOR and SF-36. This coefficient
measures the extent to which items in a scale are inter-
related. A low alpha (below 0.7) indicates insufficient
relations between the items to form a scale [25].
Test-retest reliability
The test-retest reliability of a measure is an estimate of
its reproducibility over time when no change in the
condition being assessed has taken place. The test-retest
reliability of the CAMPHOR and the SF-36 was exam-
ined by correlating scores collected at T1 and T2 using
Spearman’s rank correlation coefficients. A correlation
coefficient greater than or equal to 0.85 is required to
indicate that a scale has low random measurement error
[26]. It is important to note that the Spearman’s correl-
ation coefficient does not represent the percentage of
explained variance. To assist with the interpretation of
the correlation coefficient, the percentage of variance
explained in the CAMPHOR and SF-36 scores (r2) was
calculated. In addition, corresponding confidence inter-
vals for mean scores were provided based on the stand-
ard error of measurement (SEM) to indicate the level of
accuracy inherent in the scores. The SEM is useful for
estimating how participants may score during repeated
applications of the same measure. Confidence intervals
based on the SEM show how participants’ scores are
distributed around their ‘true scores’. Measures with
lower reliability will have higher SEM values and wider
confidence intervals. The SEM is defined in terms of the
standard deviation (δ) and the reliability (r) as follows:
SEM ¼ δ√ 1−rð Þ
Construct validity (Known group validity)
Construct validity was determined using non-parametric
tests for independent samples (Mann-Whitney U Test)
to test for differences in CAMPHOR and SF-36 scores
between groups according to disease severity (WHO




Sixty-five participants (51 females, 78.5%) were recruited
to the study. Demographic information for the sample is
shown in Table 1.Distributional properties
Total score descriptive information for the SF-36 is
shown in Table 2. Results indicated that there were high
levels of ceiling effects (% scoring maximum) for the bodily
pain, social functioning and role-emotional domains of the
SF-36 at both T1 and T2.
Total scale score descriptive information for the
CAMPHOR is shown in Table 3. Minimal levels of floor
and ceiling effects were found at each time point indicating
the scales were well matched to the disease severity levels
of the participants.
Internal consistency
The Cronbach’s alpha coefficients for the SF-36 and
CAMPHOR are shown in Table 4. Values were acceptable
(>0.70) for all scales for both measures. This indicates that
items are sufficiently related to form scales.
Test-retest reliability
Test-retest reliability, confidence intervals for mean scores
and percentage of explained variance for the SF-36 and
CAMPHOR are shown in Table 5. Test-retest reliability
was good for the SF-36 physical functioning and general
health domains. Test-retest correlations were below 0.85
for all other SF-36 domains. These SF-36 domains also
had wide confidence intervals for mean scores (indicating
score inaccuracy) and had low levels of explained variance
(r2 < 0.70).
Test-retest coefficients were good for all CAMPHOR
scales, indicating low levels of random measurement error.
Table 2 Descriptive statistics for SF-36 domains
Time 1 Physical functioning Role-physical Bodily pain General health Vitality Social functioning Role-emotional Mental health
59 60 61 60 61 61 60 61n
Median (IQR) 35.0 (20.0-50.0) 37.5 (20.3-67.2) 52.0 (41.0-74.0) 30.0 (15.0-47.0) 37.5 (18.8-59.4) 75.0 (37.5-87.5) 75.0 (50.0-97.9) 65.0 (52.5-85.0)
Mean (SD) 35.3 (21.9) 41.9 (27.9) 53.4 (25.1) 30.3 (19.8) 38.2 (23.8) 62.1 (31.1) 67.9 (31.2) 67.4 (17.9)
Range 0.0-80.0 0.0-100.0 0.0-100.0 0.0-72.0 0.0-81.3 0.0-100.0 0.0-100.0 30.0-100.0
Floor effect (% scoring min) 5.1 5.0 4.9 8.3 6.6 3.3 6.7 3.3
Ceiling effect (% scoring max) 3.4 3.3 9.8 3.3 4.9 21.3 25.0 1.6
Time 2
n 59 60 60 58 61 60 61 61
Median (IQR) 30.0 (20.0-50.0) 40.6 (25.0-73.4) 51.5 (33.5-74.0) 25.0 (13.8-42.8) 31.3 (18.8-53.1) 62.5 (37.5-87.5) 75.0 (50.0-95.8) 70.0 (55.0-85.0)
Mean (SD) 35.2 (21.7) 42.6 (28.0) 54.5 (26.5) 30.3 (21.3) 37.1 (21.3) 60.8 (29.4) 68.0 (28.3) 70.0 (18.4)
Range 0.0-90.0 0.0-100.0 0.0-100.0 0.0-87.0 0.0-81.3 0.0-100.0 0.0-100.0 25.0-100.0
Floor effect (% scoring min) 6.8 6.7 3.3 3.4 4.9 3.3 3.3 1.6





















Table 3 Descriptive statistics for CAMPHOR scales
Time 1 Symptoms Activities QoL
n 65 65 65
Median (IQR) 14.0 (7.0 – 18.5) 9.0 (5.0 – 14.5) 11.0 (4.0 – 16.0)
Mean (SD) 13.0 (6.0) 9.9 (5.9) 10.4 (6.5)
Range 2.0 – 23.0 0.0 – 24.0 0.0 – 23.0
Floor effect (% scoring min) 0.0 3.1 6.2
Ceiling effect (% scoring max) 0.0 0.0 0.0
Time 2
n 65 65 65
Median (IQR) 11.0 (7.0 – 17.0) 10.0 (6.0 – 15.0) 12.0 (5.0 – 16.0)
Mean (SD) 12.5 (6.0) 10.8 (6.1) 10.8 (6.3)
Range 1.0 – 25.0 0.0 – 23.0 0.0 – 23.0
Floor effect (% scoring min) 0.0 4.6 3.1
Ceiling effect (% scoring max) 1.5 0.0 0.0
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scales had high levels of explained variance (Table 5).
Construct validity - Known group validity
Known group validity results are shown in Table 6 and 7.
Several of the SF-36 domains distinguished between
participants based on their WHO functional classification.
However, the bodily pain and mental health domains did
not discriminate between groups at either time point
(Table 6). The role-emotional domain discriminated
between groups at T1 but not T2 (Table 6).
The CAMPHOR was able to discriminate between par-
ticipants based on WHO functional classification groups
(I&II and III&IV) at T1 and T2. Significantly higher scores
were found for WHO groups III and IV (Table 7).
Discussion
This study compared the psychometric properties of two
widely used PROMs for patients with PH. The results ofTable 4 Cronbach’s alpha coefficients for the SF-36 and
CAMPHOR
Time 1 Time 2
SF-36 Physical functioning .90 .90
Role-physical .94 .95
Bodily pain .92 .93
General health .74 .77
Vitality .88 .86
Social functioning .91 .85
Role-emotional .94 .91
Mental health .78 .81
CAMPHOR Symptoms .89 .89
Activities .91 .91
QoL .91 .91the study showed that the CAMPHOR had excellent
psychometric properties while weaknesses were apparent
in several of the SF-36 domains.
Participants were predominantly in WHO classes II
and III indicating moderately severe disease. Despite this
three of the eight SF-36 domains (social functioning,
role emotional and bodily pain) had high ceiling effects
suggesting the participants in this study had no health
problems. It is clear these domains lack sensitivity for
this patient group. This could be due to the scales
containing too few items (2-3 items each). It is also pos-
sible that the content of the items is not relevant to this
patient group.
Six of the eight SF-36 domains demonstrated inad-
equate test-retest reliability (r<0.85).Two additional
statistics were included to assist with interpreting this
finding; the percentage of explained variance and
standard error of measurement. The SF-36 domains
that did not meet acceptable levels of reliability
explained only 49-66% of variance in scores. These do-
mains also had high SEM values and wide confidence
intervals. Taken together, this indicates that six of the
eight SF-36 domains had high levels of random meas-
urement error and inaccuracy. The low reliability of
these SF-36 domains suggests that these are not ac-
ceptable as a measure intended for use in clinical trials
and other types of research in individuals with PH,
where the ability to measure changes over time is im-
portant. Only the SF-36 physical functioning and gen-
eral health domains met the required criteria in this
sample. In contrast, all of the CAMPHOR domains
met the test-retest criteria and showed low levels of
random measurement error. This indicates that, unlike
the SF-36 outcome, a change in CAMPHOR score is more
likely to represent a real change in clinical condition and/
or QoL.
Table 5 Test-retest reliability and explained variance
Test-retest % of explained variance (r2) Time 1 mean SEM Corresponding confidence intervals
SF-36 Physical Functioning .93 86 35.3 5.8 29.5-41.1
Role-Physical .81 66 41.9 12.2 29.7-54.1
Bodily Pain .72 52 53.4 13.3 40.1-66.7
General Health Perceptions .94 88 30.3 4.9 25.5-35.1
Vitality .78 61 38.2 11.2 27.0-49.4
Social Functioning .76 58 62.1 15.2 46.9-77.3
Role-Emotional .70 49 67.9 17.1 50.8-85.0
Mental Health .75 56 67.4 9.0 58.5-76.4
CAMPHOR Symptoms .86 74 13.0 2.2 10.8-15.2
Activities .87 76 9.9 2.1 7.8-12.0
QoL .94 88 10.4 1.6 8.8-12.0
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between WHO functional classification groups. However,
the bodily pain and mental health domains did not distin-
guish between groups at either time point and the role-
emotional domain did not distinguish between groups at
Time 2. Although the social functioning scale distinguished
between groups the differences in scores failed to reach the
thresholds published for the MIDs for this patient group
[20]. These findings raise further doubts about the suitabil-
ity of these domains of the SF-36 for use with this patient
group. Emotional symptoms are important features of PH.
It is likely that the role-emotional section is not specific
enough to PH to measure the construct adequately.
A recent study by Matura et al [27] in the US associated
CAMPHOR and SF-36 scores with symptom clusters in
PH patients. They found that severity of symptoms was
related to outcomes on both measures. However, they
did not explore the psychometric performance of the
measures. It was interesting to note that scores on the
psycho-social domains of the SF-36 (as in the present study)







Mean (SD) Mean (SD) Mean (SD) Mea
Time 1 (n) 59 60 61
WHO Classification
I and II 49.5 (21.6) 61.3 (26.9) 60.1 (25.9) 38.9
III and IV 27.9 (18.4) 31.4 (22.5) 49.9 (24.3) 25.7
p value <.001 <.001 .360
Time 2 (n) 59 60 60
WHO Classification
I and II 48.5 (23.8) 59.4 (20.7) 61.7 (25.8) 38.3
III and IV 28.3 (17.2) 34.2 (27.6) 50.6 (26.4) 26.4
p value .001 .001 .158
p value, Mann-Whitney U-tests.Other researchers have investigated the functioning of
the SF-36 physical (PCS) and mental (MCS) component
summaries in PH patients [28]. Chen et al reported low
levels of end effects for the MCS and PCS scales.
Considerable doubt has been raised about the validity of
the statistical methodology employed in the calculation
of these scales [29-36]. Both the PCS and MCS scores
are calculated by using factor coefficients from all eight
domains. The PCS includes positively weighted coefficients
from the physical domains of the measure but also nega-
tively weighted coefficients from the mental domains. This
means that in order to obtain the highest PCS scores it is
necessary to both have high scores on the physical domains
and low scores on the mental domains. The same is true of
the MCS. Such an approach to measurement leads to
anomalies, including the creation of artificially low end
effects. Therefore it was decided not to report PCS or MCS
scores in the present study.
Based on the findings of this study only the SF-36
physical functioning and general health perceptions







n (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
60 61 61 60 61
(18.5) 48.2 (20.5) 75.0 (27.4) 82.9 (19.3) 72.1 (17.1)
(19.1) 33.0 (24.0) 55.3 (31.1) 59.8 (33.5) 64.9 (18.0)
.009 .015 .014 .010 .165
58 61 60 61 61
(20.7) 47.9 (20.9) 72.6 (24.2) 76.2 (23.3) 73.8 (16.7)
(20.8) 31.4 (19.4) 54.5 (30.3) 63.8 (30.0) 68.0 (19.1)
.034 .005 .027 .123 .167




Mean (SD) Mean (SD) Mean (SD)
WHO classification
I and II 21 10.4 (5.3) 7.2 (5.7) 7.3 (6.1)
III and IV 44 14.3 (5.9) 11.2 (5.7) 11.9 (6.2)
p value 0.012 0.011 0.007
Time 2
WHO classification
I and II 21 10.1 (5.3) 7.7 (6.2) 7.8 (5.8)
III and IV 44 13.6 (6.0) 12.3 (5.5) 12.2 (6.1)
p value 0.031 0.003 0.006
p value, Mann-Whitney U-tests.
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perceptions section of the SF-36 is concerned with
perceptions of health and illness beliefs and the physical
functioning scale with functional limitations. These out-
comes measure only a limited aspect of patients’ experience
with PH. The results of this study demonstrate that the
CAMPHOR is a more complete tool to assess the impact of
PH from the patients’ perspective, with good psychometric
properties in all scales.
As the CAMPHOR is a disease-specific measure the
content is highly relevant to PH patients. The low levels of
floor and ceiling effects and high test-retest reliability
show the measure is sensitive and has low levels of
random measurement error. This in turn suggests the
CAMPHOR will be responsive to change. A previous
research study has provided evidence of the responsiveness
of the CAMPHOR [22].
Limitations of the study are noted. A relatively small
sample was available so the results should be interpreted
with some caution (n=65). However, this is typical of
studies in this orphan disease [16,37,38]. A high propor-
tion of females were included in the sample (78.5%).
This reflects the gender ratio prevalence in PH patients
[3]. The study was not designed to compare responsive-
ness of the two measures. Despite this, psychometric
analyses suggest that the CAMPHOR scales would be
more responsive. Overall, the study has provided a
good indication of the psychometric properties of the
two measures.
Conclusions
Only the SF-36 physical functioning and general health
perceptions domains met adequate psychometric criteria
for use in research on individuals with PH. In con-
trast, all three CAMPHOR scales met the criteria.
The CAMPHOR has superior psychometric propertiesto the SF-36 in the assessment of PH patient-reported
outcome.
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